Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
Palazzo M, Lombard-Bohas C, Cadiot G, Matysiak-Budnik T, Rebours V, Vullierme MP, Couvelard A, Hentic O, Ruszniewski P. Palazzo M, et al. Among authors: cadiot g. Eur J Gastroenterol Hepatol. 2013 Feb;25(2):232-8. doi: 10.1097/MEG.0b013e328359d1a6. Eur J Gastroenterol Hepatol. 2013. PMID: 23108416
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
de Mestier L, Walter T, Brixi H, Evrard C, Legoux JL, de Boissieu P, Hentic O, Cros J, Hammel P, Tougeron D, Lombard-Bohas C, Rebours V, Ruszniewski P, Cadiot G. de Mestier L, et al. Among authors: cadiot g. Neuroendocrinology. 2019;108(4):343-353. doi: 10.1159/000498887. Epub 2019 Feb 13. Neuroendocrinology. 2019. PMID: 30759445
Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors.
De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C, Coriat R, Cadiot G, Couvelard A, Ruszniewski P, Cros J, de Mestier L. De Rycke O, et al. Among authors: cadiot g. Endocr Relat Cancer. 2021 Jun 11;28(7):457-466. doi: 10.1530/ERC-21-0034. Endocr Relat Cancer. 2021. PMID: 33979778
New treatment strategies in advanced neuroendocrine tumours.
Walter T, Brixi-Benmansour H, Lombard-Bohas C, Cadiot G. Walter T, et al. Among authors: cadiot g. Dig Liver Dis. 2012 Feb;44(2):95-105. doi: 10.1016/j.dld.2011.08.022. Epub 2011 Oct 7. Dig Liver Dis. 2012. PMID: 21983252 Review.
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Caplin ME, et al. Among authors: cadiot g. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. N Engl J Med. 2014. PMID: 25014687 Free article. Clinical Trial.
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G, Dromain C, Farace F, Rougier P, Ducreux M. Mitry E, et al. Among authors: cadiot g. Eur J Cancer. 2014 Dec;50(18):3107-15. doi: 10.1016/j.ejca.2014.10.001. Epub 2014 Oct 18. Eur J Cancer. 2014. PMID: 25454413 Clinical Trial.
Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
Roquin G, Baudin E, Lombard-Bohas C, Cadiot G, Dominguez S, Guimbaud R, Niccoli P, Legoux JL, Mitry E, Rohmer V, Ruszniewski P, Walter T, Ducreux M, Couvelard A, Scoazec JY, Ramond-Roquin A, Caroli-Bosc FX, Hentic O. Roquin G, et al. Among authors: cadiot g. Neuroendocrinology. 2018;106(1):38-46. doi: 10.1159/000457955. Epub 2017 Feb 3. Neuroendocrinology. 2018. PMID: 28152531 Free article.
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.
Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T. Lepage C, et al. Among authors: cadiot g. Dig Liver Dis. 2017 May;49(5):568-571. doi: 10.1016/j.dld.2017.02.004. Epub 2017 Mar 11. Dig Liver Dis. 2017. PMID: 28292641 Clinical Trial.
284 results